Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-11-26
Target enrollment:
Participant gender:
Summary
The phase 1 primary objectives of this study are to assess the safety profile, characterize
pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and
recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants
with relapsed or refractory multiple myeloma. This study will also assess the safety profile
and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive
multiple myeloma.
The phase 2 primary objective is to further evaluate the objective response rate (ORR) and
very good partial response or better rate (VGPR+) in participants with t(11;14)-positive
multiple myeloma.